PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023. In the quarter to June 2026, revenue grew 147.7%, EPS grew 98.4% and free cash flow fell 45.0%, each against the same quarter a year earlier.
Follow ELAB
PMGC Holdings Inc. (ELAB) EV/Sales
As of 16 October 2026, PMGC Holdings Inc. (ELAB) trades at a EV/Sales of −6.7×. Over the past ten years it has ranged from −7.9× (June 2026) to 33,012,255× (November 2023); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −3.0× | — |
| FY2023 | −1.9× | — |
| FY2022 | 27,782,590× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −4.9× | — |
| Mar 2026 | −6.7× | — |
| Dec 2025 | −3.0× | — |
| Sep 2025 | −2.5× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. | −6.7× |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | 4.4× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. compare | 23.3× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)